New York State and Virginia health centers asked a federal district judge on Monday to deny four insulin and diabetes drug manufacturers’ motion to pause fact-finding in the health centers’ antitrust suit stemming from the companies’ 340B contract pharmacy policies.
The companies—AstraZeneca, Lilly, Novo Nordisk, and Sanofi—asked U.S. District Judge Elizabeth Wolford on Nov. 24 to stay discovery in the case pending Wolford’s decision on their Nov. 16 motion to dismiss the antitrust suit filed by health centers Mosaic Health of upstate New York and Central Virginia Health Services (CVHS).
New York State and Virginia health centers asked a federal district judge on Monday to deny four insulin and diabetes drug manufacturers’ motion to pause fact-finding in the health centers’ antitrust suit stemming from the companies’ 340B contract pharmacy policies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
